Studies in humans have shown that CJC-1295 raises IGF-1 by approximately 1.5–3 times baseline after a single dose, lasting more than a week. However, there is no established clinical monitoring protocol, „optimal range,” or blood test schedule specifically validated for individuals using CJC-1295 or ipamorelin. The IGF-1 blood test itself is a standard, well-established clinical tool. It simply has not been formally paired with monitoring guidelines for these two peptides.
How much do CJC-1295 and ipamorelin increase IGF-1?
IGF-1 is a hormone that the liver produces in response to growth hormone signals. It is often used as a marker to assess how active the growth hormone system truly is. The most pronounced quantitative data on IGF-1 rise comes from the primary human study of CJC-1295. Healthy adult volunteers were given single escalating doses under controlled clinical conditions. Researchers measured IGF-1 rise of 1.5 to 3 times above baseline following a single dose. This elevation lasted for nine to eleven days [1]. This IGF-1 response followed an initial rise in growth hormone itself. Growth hormone rose more dramatically—two to tenfold. However, it lasted somewhat shorter—six days or more. This helps explain why IGF-1 is generally considered a more useful marker to track the sustained biological activity of this compound. It rises more gradually in the liver in response to growth hormone stimulation and then stays elevated longer than the pulse of growth hormone that triggered it [1].
In the same study, when CJC-1295 was repeatedly administered over several weeks, IGF-1 remained above baseline for up to 28 days. The authors of the study specifically described evidence of a cumulative effect. This means that the elevation built up with each subsequent dose, rather than simply resetting to baseline between injections [1].
It is important to note something here. These growth multiple numbers come from one specific study population: healthy adults aged 21–61 years, using the specific doses tested (most notably 30 and 60 micrograms per kilogram). No equivalent, dedicated human study measuring IGF-1 response to ipamorelin alone, or both compounds together, was identified in the literature reviewed for this article. This means the above IGF-1 numbers should be understood as describing CJC-1295 specifically, and not the result of a combined protocol.
How long do CJC-1295 and ipamorelin need to increase IGF-1?
Based on the same research data, the IGF-1 upregulation schedule follows a fairly predictable pattern after a single dose. Growth hormone increases first, within hours. IGF-1 follows with a delay, as it has to be produced by the liver in response to the growth hormone signal, rather than being released immediately. It then reaches its own elevated plateau, which lasts for nine to eleven days after just one injection [1]. For anyone using a repeated weekly or bi-weekly schedule, similar to the pattern tested in the original studies, achieving the kind of sustained, cumulative 28-day IGF-1 elevation documented in this study would be expected to require multiple doses within that same multi-week period – not just a single injection [1].
It is worth reiterating that this schedule reflects blood hormone measurements taken in a specific, monitored clinical trial. It is not the same as a guide to when someone might notice a subjective or visible change. No study identified in this research series tracked physical or symptomatic outcomes alongside IGF-1 blood measurements.
Monitoring of IGF-1 and blood tests with CJC-1295 and Ipamorelin
A blood test for IGF-1 alone is a well-established, standard clinical laboratory tool. It is regularly used in mainstream endocrinology to help diagnose conditions such as growth hormone deficiency and acromegaly, a condition of chronic excess growth hormone. It is also used to monitor patients on legitimate, prescribed growth hormone replacement therapy. This part is well-established daily clinical practice – nothing specific to CJC-1295. What does not exist is a validated monitoring schedule, testing frequency, or an „optimal” or „safe” target IGF-1 range specifically established for users of CJC-1295 or ipamorelin outside of a formal clinical trial or prescribed medical context. These compounds have not gone through the regulatory approval process that typically produces such standardised monitoring guidelines.
This is particularly relevant to the concern of IGF-1 being „too high”. As discussed in an earlier article in this series on cancer risk, IGF-1 is recognised in mainstream endocrinology as having growth-stimulating, i.e. mitogenic, effects on cells. A 2026 scientific review that looked at performance-enhancing peptides within the growth hormone–IGF-1 axis specifically proposed that clinicians develop structured frameworks for taking exposure histories and assessing symptoms in patients taking these unregulated compounds. This proposal exists precisely because standard, formalised guidelines for interpreting laboratory results in this specific context do not yet exist [2].
In practical terms, this means something significant. If someone using these compounds actually gets a blood test for IGF-1, a significant interpretation of the result is not something this article can do. Deciding if a given number reflects an expected, non-concerning response or a level requiring attention requires more than a general reference. No validated reference range for „acceptable” self-administered IGF-1 elevation has been established. This type of interpretation requires a licensed healthcare professional who knows the individual's full clinical picture – ideally, someone with endocrinology experience – not a general online reference range.
Limitations of current evidence
The described above IGF-1 and dosing schedule growth data is well-documented specifically for CJC-1295, from a small, albeit genuine, clinical trial in humans [1].
What's missing is any equivalent data for ipamorelin itself or the two compounds together. Perhaps more importantly for anyone actually testing their own levels, there is no established, validated monitoring protocol, testing interval, or interpretative safety range specific to the off-label use of CJC-1295 or ipamorelin. This leaves a real gap between accessing laboratory testing and knowing how to safely interpret it in this context.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or guidance on interpreting laboratory results. CJC-1295 and ipamorelin remain research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. There is no validated monitoring schedule or safe reference range for IGF-1 for individuals using these compounds outside of a formal clinical trial or prescribed medical context.
References
[1] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[2] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475